Bacteria-Based Nanoprobes for Cancer Therapy
Yiping Lu,Nan Mei,Yinwei Ying,Dongdong Wang,Xuanxuan Li,Yajing Zhao,Yuqi Zhu,Shun Shen,Bo Yin
DOI: https://doi.org/10.2147/ijn.s438164
IF: 7.033
2024-01-24
International Journal of Nanomedicine
Abstract:Yiping Lu, 1, &ast Nan Mei, 1, &ast Yinwei Ying, 1, &ast Dongdong Wang, 1 Xuanxuan Li, 1 Yajing Zhao, 1 Yuqi Zhu, 1 Shun Shen, 2, 3 Bo Yin 1 1 Department of Radiology, Huashan Hospital, Fudan University, Shanghai, People's Republic of China; 2 Pharmacy Department, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People's Republic of China; 3 Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Shanghai, People's Republic of China &astThese authors contributed equally to this work Correspondence: Bo Yin; Shun Shen, Email ; Surgical removal together with chemotherapy and radiotherapy has used to be the pillars of cancer treatment. Although these traditional methods are still considered as the first-line or standard treatments, non-operative situation, systemic toxicity or resistance severely weakened the therapeutic effect. More recently, synthetic biological nanocarriers elicited substantial interest and exhibited promising potential for combating cancer. In particular, bacteria and their derivatives are omnipotent to realize intrinsic tumor targeting and inhibit tumor growth with anti-cancer agents secreted and immune response. They are frequently employed in synergistic bacteria-mediated anticancer treatments to strengthen the effectiveness of anti-cancer treatment. In this review, we elaborate on the development, mechanism and advantage of bacterial therapy against cancer and then systematically introduce the bacteria-based nanoprobes against cancer and the recent achievements in synergistic treatment strategies and clinical trials. We also discuss the advantages as well as the limitations of these bacteria-based nanoprobes, especially the questions that hinder their application in human, exhibiting this novel anti-cancer endeavor comprehensively. Keywords: bacteria-based nanoprobe, bacteria-mediated synergistic cancer therapy, nanomedicine, tumor targeting, tumor immune microenvironment, clinical trial Graphical Nowadays, cancer is considered to rank as the leading cause of death and the single most important barrier to increasing life expectancy in every country of the world in the 21st century. 1 Numerous efforts have been made to conquer cancers. Surgical resection with tumor removal is known as the first-line treatment of many kinds of tumors in their early stage, but for unresectable ones, additional tools are indispensable. Since the late 20th century, new methods, especially chemotherapy and radiotherapy, which utilizes different types of chemotherapeutic drugs or high doses of radiation, are applied to kill tumor cells and shrink tumors. When compared to chemotherapy, the utility of radiotherapy is rather limited since it is only suitable for a tumor confined to a discrete anatomical area. 2 As a systemic therapy, chemotherapy with anti-tumor drugs is capable to treat cancer throughout the whole body even with metastasis. 3 However, the therapeutic effect of chemotherapy is often modest. It was reported that cancer treatment based on a broad use of cytotoxic chemotherapy in unselected cancer patients had reached its therapeutic plateau. 4 Furthermore, the systemic toxicity caused by the lack of selectivity and resistance to chemotherapy and radiotherapy had also severely hampered the effectiveness of these traditional treatments. 5 Therefore, the need to find better treatment alternatives was underscored. The phenomenon of the selective accumulation of nanometric devices into tumoral tissues discovered first by Matsumura and Maeda in 1986, known as enhanced permeation and retention (EPR) effect, has given nanomedicine an advantage over conventional medicine and started a new chapter of nanomedicine against cancer. 6,7 Since then, hundreds of different nanoparticle (NP)-based drug delivery systems (DDSs) have been developed, from inorganic systems, or organic ones, to hybrid NPs. Theoretically, when administered systemically, NPs leak from the tumor blood vessels into the tumor interstitium through the hyperpermeable tumor vasculatures and are then retained in the tumor due to reduced lymphatic drainage which could potentially increase the effectiveness of anti-tumor drugs. 8 The characteristics including passive accumulation within tumor via EPR effect, decoration of various targeting ligands and multiple types of triggers of payload release enable NPs to achieve excellent performance in vitro and in vivo models. 9–13 However, the nano-delivery system mainly based on EPR effect could not always achieve satisfactory therapeutic -Abstract Truncated-
pharmacology & pharmacy,nanoscience & nanotechnology